NCT06667154View on ClinicalTrials.gov

Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

October 10, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2027

Conditions
Lung Cancer, Nonsmall CellNon-Small Cell Lung Cancer NSCLC
Interventions
DRUG

Low-dose nivolumab combined with platinum-based doublet chemotherapy

Platinum-based neoadjuvant chemotherapy (carboplatin at AUC 5 or 6 combined with either paclitaxel at 175 mg/m² or pemetrexed at 500 mg/m²), administered with nivolumab at 0.3 mg/kg every 21 days for 3 cycles.

Trial Locations (1)

15090000

RECRUITING

Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto, São José do Rio Preto

All Listed Sponsors
collaborator

Hospital de Base de Sao Jose do Rio Preto

UNKNOWN

lead

Aline Fusco Fares, MD

OTHER